The agreement unites MilliporeSigma's strength in organoids and synthetic chemistry with Promega's market leading assay and reporter technologies.
The agreement unites MilliporeSigma's strength in organoids and synthetic chemistry with Promega's market leading assay and reporter technologies. Together, the companies aim to develop assays capable of tracking cellular activity in real time using an innovative reporter system within three-dimensional (3D) cell cultures. These 3D cell cultures, also called organoids, mimic the human biology, where testing can be done in a model that is physiologically more relevant than traditional two-dimensional (2D) models.